REG - OptiBiotix Health - Change of Adviser <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

10/12/2014 07:11

RNS Number : 2984Z
OptiBiotix Health PLC
10 December 2014
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Appointment of Joint Broker
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, is pleased to announce the appointment of Hybridan LLP as joint broker with immediate effect. 
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Cairn Financial Advisers LLP
Nominated Adviser
Tel: 020 7148 7900
Liam Murray / Avi Robinson

Peterhouse Corporate Finance Ltd
Joint Broker
Tel: 020 7469 0936
Lucy Williams / Duncan Vasey

Hybridan LLP
Joint Broker
Claire Louise Noyce
Tel: 020 3713 4581
Walbrook PR Ltd
Financial PR
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
Mike Wort
Mob: 07900 608 002
About OptiBiotix- www.optibiotix.com 
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
APPLLFVRFALAIIS